Pfizer
This article was originally published in The Tan Sheet
Executive Summary
Receives warning letter from FDA on June 3 regarding "allergy relief" claims for Visine AC eye drops. The agency noted that OTC ophthalmic vasoconstrictor drugs may only be indicated for "relieves redness of the eye due to minor eye irritations" and not for allergies. Pfizer said it plans to "fully cooperate" with the agency
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning